DK2822656T3 - 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use - Google Patents

3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use Download PDF

Info

Publication number
DK2822656T3
DK2822656T3 DK13709994.1T DK13709994T DK2822656T3 DK 2822656 T3 DK2822656 T3 DK 2822656T3 DK 13709994 T DK13709994 T DK 13709994T DK 2822656 T3 DK2822656 T3 DK 2822656T3
Authority
DK
Denmark
Prior art keywords
independently
present
compound according
optionally substituted
saturated
Prior art date
Application number
DK13709994.1T
Other languages
Danish (da)
English (en)
Inventor
Alan Ashworth
Christopher James Lord
Richard James Rowland Elliott
Dan Niculescu-Duvaz
Roderick Porter
Raymond John Boffey
Melanie Jayne Bayford
Stuart Firth-Clark
Ashley Nicholas Jarvis
Trevor Robert Perrior
Rebekah Elisabeth Key
Original Assignee
Inst Of Cancer Research: Royal Cancer Hospital (The)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Cancer Research: Royal Cancer Hospital (The) filed Critical Inst Of Cancer Research: Royal Cancer Hospital (The)
Application granted granted Critical
Publication of DK2822656T3 publication Critical patent/DK2822656T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK13709994.1T 2012-03-07 2013-03-07 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use DK2822656T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607680P 2012-03-07 2012-03-07
PCT/GB2013/050561 WO2013132253A1 (en) 2012-03-07 2013-03-07 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use

Publications (1)

Publication Number Publication Date
DK2822656T3 true DK2822656T3 (en) 2017-01-30

Family

ID=47891779

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13709994.1T DK2822656T3 (en) 2012-03-07 2013-03-07 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use

Country Status (13)

Country Link
US (1) US9193689B2 (cg-RX-API-DMAC7.html)
EP (1) EP2822656B1 (cg-RX-API-DMAC7.html)
JP (1) JP6082409B2 (cg-RX-API-DMAC7.html)
KR (1) KR102104144B1 (cg-RX-API-DMAC7.html)
CN (1) CN104302358B (cg-RX-API-DMAC7.html)
AU (1) AU2013229229B2 (cg-RX-API-DMAC7.html)
CA (1) CA2865511A1 (cg-RX-API-DMAC7.html)
DK (1) DK2822656T3 (cg-RX-API-DMAC7.html)
ES (1) ES2611504T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014MN01875A (cg-RX-API-DMAC7.html)
MX (1) MX346147B (cg-RX-API-DMAC7.html)
RU (1) RU2696572C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013132253A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346147B (es) 2012-03-07 2017-03-09 Inst Of Cancer Research: Royal Cancer Hospital (The) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
RU2654216C2 (ru) 2012-08-08 2018-05-17 Мерк Патент Гмбх Производные (аза-)изохинолинона
US9611223B2 (en) * 2013-09-11 2017-04-04 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
WO2017059191A1 (en) * 2015-09-30 2017-04-06 Quartet Medicine, Inc. Heteroaryl derivatives as sepiapterin reductase inhibitors
JP6930972B2 (ja) 2015-12-02 2021-09-01 シンジェンタ パーティシペーションズ アーゲー 殺微生物性オキサジアゾール誘導体
UY37623A (es) 2017-03-03 2018-09-28 Syngenta Participations Ag Derivados de oxadiazol tiofeno fungicidas
CN110709395A (zh) 2017-06-02 2020-01-17 先正达参股股份有限公司 杀微生物的噁二唑衍生物
WO2018219773A1 (en) 2017-06-02 2018-12-06 Syngenta Participations Ag Fungicidal compositions
CA3067309A1 (en) 2017-06-28 2019-01-03 Syngenta Participations Ag Fungicidal compositions
BR112020000465B1 (pt) 2017-07-11 2024-02-20 Syngenta Participations Ag Derivados oxadiazol microbiocidas
WO2019011928A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
WO2019011926A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
WO2019011929A1 (en) 2017-07-11 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
WO2019012011A1 (en) 2017-07-12 2019-01-17 Syngenta Participations Ag MICROBIOCIDE OXADIAZOLE DERIVATIVES
BR112020000463A2 (pt) 2017-07-13 2020-07-21 Syngenta Participations Ag derivados oxadiazol microbiocidas
EP3459469A1 (en) 2017-09-23 2019-03-27 Universität Zürich Medical occluder device
US12402885B2 (en) 2017-09-23 2025-09-02 Universität Zürich Medical occlusion device
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
WO2020016180A1 (en) 2018-07-16 2020-01-23 Syngenta Crop Protection Ag Microbiocidal oxadiazole derivatives
CN114040915B (zh) 2019-04-12 2025-07-15 里伯赛恩斯有限责任公司 作为外核苷酸焦磷酸酶磷酸二酯酶1抑制剂的双环杂芳基衍生物
AR118673A1 (es) * 2019-04-18 2021-10-20 Syngenta Crop Protection Ag Procedimiento para la preparación de derivados de oxadiazol microbiocidas
CN114641242B (zh) 2019-09-26 2025-11-18 苏黎世大学 左心耳闭塞装置
MX2022005234A (es) * 2019-10-30 2022-09-07 Digmbio Inc Derivados de isoquinolinona, procedimiento para su preparacion y composicion farmaceutica para la prevencion o el tratamiento de enfermedades relacionadas con la poli(adp-ribosa) polimerasa-1, que constituye los mismos como principio activo.
WO2022087269A1 (en) 2020-10-21 2022-04-28 Verint Americas Inc. System and method of automated determination of use of sensitive information and corrective action for improper use
WO2022194799A1 (de) 2021-03-18 2022-09-22 Merck Patent Gmbh Heteroaromatische verbindungen für organische elektrolumineszenzvorrichtungen
WO2022235492A1 (en) * 2021-05-04 2022-11-10 Board Of Regents, The University Of Texas System Indanone and tetralone-keto or hydroxyl oximes as cancer therapeutics
EP4444305A2 (en) * 2022-02-16 2024-10-16 Duke Street Bio Limited Pharmaceutical compound
CN115572262B (zh) * 2022-10-27 2024-08-27 厦门沃克沃德医药科技有限公司 一种异喹啉衍生物及其制备方法
WO2024238871A1 (en) * 2023-05-18 2024-11-21 Rectify Pharmaceuticals, Inc. Aryl sulfonamide compounds and their use in treating medical conditions
GB2634228A (en) * 2023-10-02 2025-04-09 Duke Street Bio Ltd PARP1 inhibitor compounds
WO2025136936A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Agonists of trem2 activity

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2851458A (en) 1955-06-08 1958-09-09 Burroughs Wellcome Co Diquaternary compounds and the manufacture thereof
US3464563A (en) 1967-02-06 1969-09-02 American Air Filter Co Liquid filter apparatus
US4678500A (en) 1984-06-29 1987-07-07 E. I. Du Pont De Nemours And Company Herbicidal 2,6-disubstituted benzylsulfonamides and benzenesulfamates
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US4942163A (en) 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
WO1999018077A1 (en) 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
RS51444B (sr) 2001-09-21 2011-04-30 Bristol-Myers Squibb Company JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
MXPA05000983A (es) * 2002-07-24 2005-08-18 Kyorin Seiyaku Kk Derivados de 4-(aril substituido)-5-hidroxiisoquinolinona.
DK1557414T3 (da) 2002-10-01 2012-05-29 Mitsubishi Tanabe Pharma Corp IsoquinoIin-forbindelser og medicinsk anvendelse deraf
JP2006506379A (ja) 2002-10-23 2006-02-23 グレンマーク・ファーマシューティカルズ・リミテッド 炎症性およびアレルギー性疾患の治療に有用な新規三環式化合物：その調製方法およびそれらを含む医薬組成物
ATE496893T1 (de) 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc Isochinolinonderivate und deren verwendung als medikamente
US7173004B2 (en) 2003-04-16 2007-02-06 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
WO2005075432A1 (ja) 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
WO2005113540A1 (ja) 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation イソキノリン化合物及びその医薬用途
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
JP5046950B2 (ja) 2004-10-22 2012-10-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃ−ｆｍｓキナーゼのインヒビター
MX2007007027A (es) 2004-12-16 2007-07-04 Hoffmann La Roche Derivados piperazinilpiridina como agentes anti-obesidad.
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
BRPI0609625A2 (pt) 2005-03-31 2010-04-20 Astellas Pharma Inc derivados de propano-1,3-diona ou sal destes
WO2007016525A2 (en) 2005-07-29 2007-02-08 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US7652028B2 (en) * 2005-08-24 2010-01-26 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
CN101511796B (zh) 2006-09-05 2012-05-09 协和发酵麒麟株式会社 咪唑衍生物
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009027650A1 (en) 2007-08-24 2009-03-05 The Institute Of Cancer: Royal Cancer Hospital Materials and methods for exploiting synthetic lethality in brca-associated cancers
US20100267626A1 (en) 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
DE102008019838A1 (de) 2008-04-19 2009-12-10 Boehringer Ingelheim International Gmbh Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
US8431704B2 (en) 2008-04-22 2013-04-30 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted P2X7 antagonists
EP2362775B1 (en) 2008-11-20 2015-08-05 GlaxoSmithKline LLC Chemical compounds
KR20110122874A (ko) 2009-03-06 2011-11-11 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
EP2408454B1 (en) 2009-03-18 2024-07-24 Resverlogix Corp. Novel anti-inflammatory agents
CN102458405B (zh) 2009-04-22 2017-06-23 雷斯韦洛吉克斯公司 新抗炎剂
TWI499418B (zh) 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物
US8841289B2 (en) 2009-10-13 2014-09-23 Merck Sharp & Dohme B.V. Heterocyclic derivatives
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013528635A (ja) 2010-06-17 2013-07-11 ノバルティス アーゲー ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
WO2013012723A1 (en) 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
JP2014520860A (ja) 2011-07-13 2014-08-25 ノバルティス アーゲー タンキラーゼ阻害剤として使用するための４−オキソ−３，５，７，８−テトラヒドロ−４Ｈ−ピラノ｛４，３−ｄ｝ピルミニジニル化合物
US9163003B2 (en) 2011-07-13 2015-10-20 Novartis Ag 4-piperidinyl compounds for use as tankyrase inhibitors
WO2013076090A1 (en) 2011-11-25 2013-05-30 Nerviano Medical Sciences S.R.L. 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors
US9328111B2 (en) 2011-12-31 2016-05-03 Beigene Ltd. Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors
NO2797921T3 (cg-RX-API-DMAC7.html) 2011-12-31 2018-02-03
CN104080773B (zh) 2012-01-28 2016-12-28 默克专利股份公司 氮杂环化合物
WO2013116182A1 (en) 2012-01-31 2013-08-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
DK2812323T3 (en) 2012-02-09 2016-05-09 Merck Patent Gmbh TETRAHYDRO-quinazolinone derivatives BY TANKERS AND PARPINHIBITORER
US9340549B2 (en) 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
MX346147B (es) 2012-03-07 2017-03-09 Inst Of Cancer Research: Royal Cancer Hospital (The) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
ES2585044T3 (es) 2012-03-28 2016-10-03 Merck Patent Gmbh Derivados de pirazinona bicíclicos
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
HUE028325T2 (en) 2012-05-04 2016-12-28 Merck Patent Gmbh Pyrrolotriazines derivatives
WO2013177349A2 (en) 2012-05-25 2013-11-28 Glaxosmithkline Llc Quinazolinediones as tankyrase inhibitors
EP2858995A1 (en) 2012-06-07 2015-04-15 F. Hoffmann-La Roche AG Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
CN104540830A (zh) 2012-06-07 2015-04-22 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂
WO2013189904A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Pyranopyridone inhibitors of tankyrase
KR20150011838A (ko) 2012-06-20 2015-02-02 에프. 호프만-라 로슈 아게 탄키라아제 억제제로서의 피롤로피라존
RU2654216C2 (ru) 2012-08-08 2018-05-17 Мерк Патент Гмбх Производные (аза-)изохинолинона
EP2890696A1 (en) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
AR092211A1 (es) 2012-09-24 2015-04-08 Merck Patent Ges Mit Beschränkter Haftung Derivados de hidropirrolopirrol
BR112015006524A8 (pt) 2012-09-26 2019-08-20 Merck Patent Gmbh derivados de quinazolinona como inibidores de parp, seu processo de preparação, seu uso, medicamentos e conjunto (kit)
WO2014087165A1 (en) 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors

Also Published As

Publication number Publication date
US20150099732A1 (en) 2015-04-09
JP6082409B2 (ja) 2017-02-15
AU2013229229B2 (en) 2017-10-19
CA2865511A1 (en) 2013-09-12
KR102104144B1 (ko) 2020-04-23
CN104302358A (zh) 2015-01-21
EP2822656A1 (en) 2015-01-14
RU2014138194A (ru) 2016-04-27
KR20150001734A (ko) 2015-01-06
CN104302358B (zh) 2017-12-05
ES2611504T3 (es) 2017-05-09
JP2015512885A (ja) 2015-04-30
MX2014010509A (es) 2014-10-14
MX346147B (es) 2017-03-09
WO2013132253A1 (en) 2013-09-12
US9193689B2 (en) 2015-11-24
IN2014MN01875A (cg-RX-API-DMAC7.html) 2015-07-03
RU2696572C2 (ru) 2019-08-05
EP2822656B1 (en) 2016-10-19
AU2013229229A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
DK2822656T3 (en) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
DK3044221T3 (en) 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ON COMPOUNDS AND THERAPEUTIC APPLICATION THEREOF
US8530468B2 (en) Bicyclylaryl-aryl-amine compounds and their use
DK3107914T3 (en) PYRAZOLO [1,5-A] PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THERAPEUTIC APPLICATION THEREOF
DK2197874T3 (en) Pyrazin-2-YL-PYRIDIN-2-YL-AMINE AND pyrazin-2-yl-pyrimidine-4-YL-AMINE COMPOUNDS AND THEIR USE
KR20180006334A (ko) 신규한 4-아미노피라졸로[3,4-d]피리미디닐아자바이사이클로 유도체 및 이를 포함하는 약학 조성물
US12473303B2 (en) 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use
WO2011093365A1 (ja) 含窒素複素環化合物
AU2024231943A1 (en) Biarylamide derivatives and their use as pkmyt1 inhibitors
HK40005135A (en) Pyrazole derivatives, compositions and therapeutic use thereof
HK1231852B (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
HK1231852A1 (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use